Psychiatr. pro Praxi, 2001; 3: 125-127

Antipsychotika a QT interval

prof. MUDr. Jaromír ©vestka DrSc
Psychiatrická klinika LF MU a FN Brno

Published: December 31, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©vestka J. Antipsychotika a QT interval. Psychiatr. praxi. 2001;2(3):125-127.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Arci AA, Henretig FM. Effects of risperidone in overdose. Am. J. Emerg. Med. 1998; 16: 498-501. Go to original source... Go to PubMed...
    2. Barnes TRE, McPhillips MA. Critical analysis and comparison of the sideeffect and safety profiles of the new antipsychotics. Br. J. Psychiatry 1999; 174 (Suppl. 38): 34-43. Go to original source...
    3. Baątecký J, Kvasnička J, Vortel J et al. Sebevraľedné poľití thioridazinu jako příčina závaľné poruchy srdečního rytmu - polymorfní komorové tachykardie. Čs. psychiatrie 1990; 86: 264-268.
    4. Buckley NA, Whyte IM, Dawson AH. Cardiotoxicity more common in thioridazine overdose than in other neuroleptics. J. Toxicol. Clin. Toxicol. 1995; 33: 199-204. Go to original source... Go to PubMed...
    5. Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Safety 2000; 23: 215-228. Go to original source... Go to PubMed...
    6. Czekalla J, Kollack-Walker S, Beasley CM. Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. J. Clin. Psychiatry 2001; 62 (Suppl. 2): 35-40.
    7. De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur. J. Clin. Pharmacol. 2000; 56: 1-18. Go to original source... Go to PubMed...
    8. European Agency for the Evaluation on Medicinal Products: Overall summary of the scientific evaluation of sertindole. CPMP/1784/99-EN, EMEA 2000; 2-6 (www.eudra.org/emea.html).
    9. Fulop G, Phillips RA, Shapiro AK et al. ECG changes during haloperidol and pimozide treatment of Tourette´s disorder. Am. J. Psychiatry 1987; 144: 673-675. Go to original source... Go to PubMed...
    10. Gajwani P, Pozuelo L, Tesar GE. QT interval prolongation associated with quetiapine (Seroquel) overdose. Psychosomatics 2000; 41: 63-65. Go to original source... Go to PubMed...
    11. Gury C, Canceil O, Iaria P. Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhytmia. Encephale 2000; 26: 62-72.
    12. Hatta K, Takahashi T, Nakamura H et al. Prolonged QT interval in acute psychotic patients. Psychiatr. Res. 2000; 94: 279-285. Go to original source... Go to PubMed...
    13. Jackson T, Ditmanson L, Phibbs B. Torsade de pointes and low-dose oral haloperidol. Arch. Intern. Med. 1997; 157: 2013-2015. Go to original source... Go to PubMed...
    14. Kang UG, Kwon JS, Ahn YM, Chung SJ et al. Electrocardiographic abnormalities in patients treated with clozapine. J. Clin. Psychiatry 2000; 61: 441-446. Go to original source... Go to PubMed...
    15. Kiriike N, Maeda Y, Nishiwaki S et al. Iatrogenic torsedes de pointes induced by thioridazine. Biol. Psychiatry 1987; 22: 99-103. Go to original source... Go to PubMed...
    16. Lávička V. Antipsychotika z pohledu internisty. Psychiatrie pro praxi 2000; 1: 96-102.
    17. Lawrance KR, Nasraway SA. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill. Pharmacotherapy 1997; 17: 531-537. Go to PubMed...
    18. Mechcatie E. Orap manufacturer warns of sudden deaths. Clin. Psychiatry News 1999; 27: 4.
    19. Montaz L, Varache N, Harry P et al. Torsades de pointes during sultopride poisoning. J. Toxicol. Clin. Exp. 1992; 12: 481-486. Go to PubMed...
    20. Ravin DS, Levenson JW. Fatal cardiac event following initiation of risperidone therapy. Ann. Pharmacother. 1997; 31: 867-870. Go to original source... Go to PubMed...
    21. Reilly JG, Ayis SA, Ferrier IN et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355: 1048-1052. Go to original source... Go to PubMed...
    22. Sharma ND, Rosman HS, Padhi DI, Tisdale JE. Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am. J. Cardiol. 1998; 81: 238-240. Go to original source... Go to PubMed...
    23. Springuel P. Drugs causing prolongation of QT interval and torsades de pointes. Canadian Adverse Drug Reaction Newsletter, January 1998 (www.hc.sc.gc.ca/hpb-dgps/therapeut/zfiles/english/publicat/adrv8n1_e.html).
    24. Su KP, Chen KP, Shen WW, Tsai SY. QTc prolongation associated with sulpiride and haloperidol use: a pilot crossover-design study. Eur. Neuropsychopharmacol. 2000; 10 (Suppl. 3): 311. Go to original source...
    25. Tracqui A, Mutter-Schmidt C, Kintz P et al. Amisulpride poisoning: a report of two cases. Hum. Exp. Toxicol. 1995; 14: 294-298. Go to original source... Go to PubMed...
    26. Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999; 354: 1625-1633. Go to original source... Go to PubMed...
    27. Waterlow M. Antipsychotic QT-interval concerns: droperidol to be withdrawn, thioridazine to go second-line. www.emental-health.com.
    28. Welch R, Chue P. Antipsychotic agents and QT changes. J. Psychiatry Neurosci. 2000; 25: 54-60.
    29. WHO: Sertindole (Serdolect) - suspended: cardiac arrhytmias and sudden cardiac deaths. Alert No. 78: Sertindole (Serdolect) 1998.
    30. Woosley RL. Drugs that prolong the QT interval and/or induce torsades de pointes. www.Torsades.org, www.georgetown.edu/departments/pharmacology/torsades.html.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.